Dr. Chien is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1825 Fourth St
Helen Diller Comprehensive Cancer Center
San Francisco, CA 94158Phone+1 415-353-7070Fax+1 415-353-9898
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Massachusetts General HospitalResidency, Internal Medicine, 2003 - 2006
Harvard Medical SchoolClass of 2003
Certifications & Licensure
CA State Medical License 2006 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Investigating the Impact of Tamoxifen Therapy on Ovarian Aging Start of enrollment: 2011 Jun 01
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Start of enrollment: 2020 Feb 05
Publications & Presentations
PubMed
- 108 citationsExhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.Manuela Terranova-Barberio, Nela Pawlowska, Mallika Sachdev Dhawan, Mark M. Moasser, Amy Jo Chien
Nature Communications. 2020-07-17 - 40 citationsNeoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer
Nature Communications. 2021-11-05 - 424 citationsEffect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adapt...Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai
JAMA Oncology. 2020-05-01
Lectures
- A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast canc...2019 ASCO Annual Meeting - 6/1/2019
- UCSF Asian Health SymposiumUniversity of California, San Francisco, California - 2/9/2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
